These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11985367)

  • 1. Orlistat: a second look. At best, a minor adjunct to dietary measures.
    Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orlistat. No hurry...
    Can Fam Physician; 1999 Oct; 45():2331-3, 2336-8, 2343-5 passim. PubMed ID: 10540693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orlistat: new preparation. No hurry . .
    Prescrire Int; 1999 Aug; 8(42):99-104. PubMed ID: 11503834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orlistat.
    Wong NN; Cheng-Lai A
    Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orlistat half the dose without a prescription: new status. In excess body weight: often uncomfortable and don't expect miracles. Frequent gastrointestinal disturbances for a weight loss of a few kilos. Better to encourage dietary measures, exercise and individualised support.
    Prescrire Int; 2009 Jun; 18(101):101. PubMed ID: 19637413
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M; Helgeland M; Tonstad S
    J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
    Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
    Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV; Wilton LV; Shakir SA
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of orlistat in weight management.
    Marks S
    Aust Fam Physician; 2001 Apr; 30(4):335-8. PubMed ID: 11355219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
    Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
    Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
    Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute pancreatitis following orlistat therapy: report of two cases.
    Ahmad FA; Mahmud S
    JOP; 2010 Jan; 11(1):61-3. PubMed ID: 20065556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
    Erdmann J; Lippl F; Klose G; Schusdziarra V
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A; Aydin N; Topsever P; Filiz M; Oztürk A; Dağar A; Kilinç E; Ekmekcioglu C
    Biomed Pharmacother; 2004 Dec; 58(10):582-7. PubMed ID: 15589067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
    Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.